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MMF
(n¼117)
Placebo
(n¼119)
P value
GvHD free survival at
day 56
61% (52-70%) 52% (43-61%) 0.78 *
CGvHD at 6 mo 24% (16-32%) 27% (18-35%) 0.69 y
Non relapse mortality
at 6 mo
16% (9-22%) 20% (13-28%) 0.83 y
Overall survival at 6 mo 71% (62-79%) 74% (65-81%) 0.25z
* Chi-square test.
y Gray's test.
z Log-rank test.
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contribute to the pathophysiology of cGVHD. Thus, small
molecule inhibitors of Syk may represent a potential thera-
peutic option for patients with cGVHD.
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Steroids are accepted standard primary therapy for
aGvHD, but durable responses are infrequent. A prior trial
conducted by the BMT CTN (0302) tested the addition of 1 of
4 agents to steroids as initial therapy and found mycophe-
nolate mofetil (MMF) to be the most promising for further
investigation. In this context, a phase III, multi-center
randomized trial BMT CTN 0802, sponsored by the NHLBI
and NCI, was initiated to test the addition of MMF/placebo to
steroids as initial therapy for aGvHD. Patients with any grade
of newly diagnosed aGvHD were eligible if they required
systemic therapy. The primary study objective was GvHD
free survival at day 56 after initiation of therapy. All patients
received prednisone at 2 mg/kg/day (or equivalent) with
either MMF (1000mg PO/IV q8h or 20 mg/kg for patients
<60kg) or placebo. Taper of steroids was allowed no sooner
than 3 days into study therapy, at the discretion of the
treating physician, but the protocol required treatment with
prednisone at a dose of at least 0.25 mg/kg/day of prednisone
until day 28. MMFwas continued until day 56 or until steroid
discontinuation if sooner. Patients who developed aGvHD
while on MMF prophylaxis or after unplanned DLI were
excluded. Patients who had previously received MMF for
prophylaxis were eligible if they had not received any MMF
in the previous week. All patients needed to be engrafted.
The study speciﬁed a futility rule for GVHD free survival at
day 56 and the rule was met at a planned interim analysis
after 236 patients (out of 372) were enrolled from 36 centers:
117 toMMF,119 to placebo. Baseline characteristics werewell
balanced between treatment groups. Grade of GvHD atrandomizationwas I/II (65%), III (28%) and IV (6%). GvHD free
survival at day 56 after randomization was: MMF 69 pts
(60.5%; 95% CI 51.6-69.5), placebo 60 pts (52.2%; 95% CI 43.0-
61.3) P ¼ .78. Chronic GvHD developed in 38 patients on
MMF: 6 month (mo) estimate: 23.7% (95% CI 15.9-31.6), and
39 patients on placebo: 6 mo estimate: 26.5% (95% CI 18.3-
34.7) P ¼ .69. Overall survival at 6 mo, EBV reactivation,
cumulative incidence of severe, life threatening, or fatal
infections were similar. Cytopenias were more common in
the MMF arm, while hyperglycemia was more common in
the placebo arm. Cumulative incidence estimates for non
relapse mortality at 6 mo was similar in both arms: MMF
15.5% vs. placebo 20.1%. p¼0.83. Estimated 6 mo overall
survival was 71.3% forMMFand 73.8% for placebo P¼ .25. The
addition of MMF to steroids as ﬁrst line therapy for patients
with aGvHD does not result in improved GvHD free survival
compared to treatment with steroids alone.
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Atorvastatin (ATOR) is a potent immunomodulatory agent
that holds promise as a novel and safe agent for aGVHD
prophylaxis. In murine models ATOR administration to both
donor and recipient mice, prevented aGVHD by inhibiting
donor T-cell proliferation, inducing TH-2 polarization, and by
inhibiting recipient antigen presenting cell function.
We conducted a phase II study (NCT01175148) to evaluate
the safety and efﬁcacy of ATOR administration for aGVHD
prophylaxis, to both adult donors and recipients of MRD
alloHCT. As aGVHD prophylaxis, ATOR (40mg/day PO) was
administered to sibling donors, starting 14-28 days before
the anticipated 1st day of stem cell collection. In alloHCT
recipients aGVHD prophylaxis consisted of tacrolimus,
micro-dose methotrexate and ATOR (40mg/day) adminis-
tered from day -14 to day +180. Ex vivo or in vivo T-cell
depletion was not permitted. Primary outcomes were rate of
grade (Gr) II-IV aGVHD at day 100 and safety of ATOR
administration to alloHCT donors/recipients. We tested the
null hypothesis H0: p35%, vs. the alternate H1: p15%;
where p is the probability of Gr II-IV aGVHD at day 100.
Table 1
Patients
N¼30 (range)
Male pts 20
Median age, yrs 55 (22 - 72)
Median days on statin 190 (60 - 199)
Median KPS 85 (70 -100)
Median HCT-CI 1.5 (0 - 5)
CIBMTR Disease Risk _
Low 10
Intermediate 9
High 11
Diagnosis _
AML 8
CML/CMML 2
MDS/MPD 5
CLL/SLL 2
NHL/Hodgkin 11
Others 2
Chemorefractory 11
Prior autograft 5
10/10 HLA match 30
Conditioning _
RIC 16
Myeloablative 14
Peripheral blood graft 30
ABO mismatched 10
Female donor to male patient 10
Median infused CD34 cells/kg 4.1 x 106
Median infused CD3 cells/kg 33.2 x 107
Median Follow-up of survivors, days 222 (11-717)
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donor/recipient pairs was completed. Median donor age was
52.5 yrs (range 24-75). ATOR prophylaxis in healthy donors
(median duration 14 days [range 7-24]), was not associated
with any Gr 3-4 adverse events (AEs). Table 1 shows baseline
patient (pt) characteristics. No ATOR related Gr 2-4 AEs were
seen. Themedian time to ANC500/mL was 18 days (range 5-
25) and to platelets 20k/mL was 15 days (range 11-51). The
median day 100 chimerismwas 80.5% for T-cells and 100% for
myeloid cells. Respective numbers at day 180 are 100% and
100%. Among 29 evaluable pts (1 pt waiting to engraft), the
cumulative incidence (CI) of Gr II-IV and IIIeIV aGVHD at day
100 are 3.7 3.7% and 0% respectively. Respective, rates at
day 180 are 13 7.3% and 9.1 7.3%. CI of mild/moderate and
severe chronic GVHD at 1 year are 26 11.5% and 23.5 
10.7%, respectively. Only 2 pts had CMV reactivation. Non-
relapse mortality was 0% at day 100 and 5% at day 180. CI of
relapse at day 180 was 19.7%. 1-year progression-free and
overall survival estimates are 68% and 69%, respectively.
A two-pronged strategy of ATOR administration to both
donors and recipients of MRD alloHCT appears to be
a feasible, safe and effective method for aGVHD prophylaxis.
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of MichiganWe have recently described an algorithm combining
biomarkers and clinical characteristics that, at the onset of
acute GVHD symptoms, predicts outcomes such as treatment
response and non-relapse mortality (NRM). We have now
evaluated whether a combination of pre-HCT clinical char-
acteristics and a biomarker panel measured early post-HCT
can predict future GVHD.
From 2001-2011, we prospectively collected clinical data
and plasma samples from 393 patients receiving related
donor HCT at our institution. The cumulative incidence of
grade 2-4 GVHD by day 100 was 31% (n ¼ 121; median onset
¼ day 40). We divided patients randomly into a training set
(n¼264) to develop GVHD predictive algorithms using
logistic regression, and a validation set (n¼129) to test the
algorithms. There were no statistically signiﬁcant differences
in pre-HCT clinical parameters between the 2 sets. We
measured 4 GVHD biomarkers (IL-2Ra, TNFR1, elaﬁn, and
REG3a) on post-HCT day 7 plasma samples by ELISA.
Grade 2-4 GVHD onset within 2 months of HCT served
as the predictive endpoint. We developed 3 predictive
models for GVHD in the training set: 5 validated clinical
risk factors alone (patient age, myeloablative conditioning
[MA]), HLA-match, GVHD prophylaxis, graft source, use of
TBI); the 4 biomarker panel alone; and a combination of all
9 clinical and biomarker parameters. We compared all 3
models at a speciﬁcity of 50% for their respective sensitiv-
ities. Clinical factors alone provided 51% sensitivity, 4
biomarkers alone provided 66% sensitivity, and all 9
parameters combined provided 77% sensitivity (combined
vs. clinical model, P < .001; vs. biomarker model, P ¼ .07).
The combined model provided similar sensitivity in the
validation set (75%) which allowed us to combine the 2 sets
for further analyses.
We used the algorithm to stratify patients as high
(N¼211) or low risk (n¼182) for developing GVHD. High risk
patients were twice as likely to develop grade 2-4 GVHD
(Figure 1A; 38% vs. 20%, P < .001) which developed almost 1
month earlier than in the low risk group (median day ¼ 39
vs. 65). The greater incidence of GVHD in high risk patients
resulted in signiﬁcantly greater NRM by day 180 post-HCT
(Figure 1B; 12% vs. 3%; P ¼ .001). The relapse rate was
identical in both groups (24%), thus overall survival (OS) was
signiﬁcantly better in the low risk group (84% vs. 73%, P ¼
.004). The differences between high and low risk patients
remained signiﬁcant at 1-yr post-HCT for NRM (17% vs. 6%, P
< .001) and OS (61% vs. 72%, P ¼ .01).
In conclusion, combining a panel of 4 biomarkers at day 7
post-HCT and 5 pre-HCT clinical parameters produced the
best algorithm to predict GVHD following related donor HCT.
The algorithm successfully stratiﬁed patients into high and
low risk groups for GVHD, NRM and OS. We hypothesize the
use of such an algorithm may permit preemptive therapy for
patients who are at greatest risk in the early transplant
course.
Figure 1.
